EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology

Riccardo Castagnoli iD, Martina Votto iD, Ivan Taietti iD, Maria Isabel Delgado-Dolset iD, Rubén Fernández-Santamaría iD, Martha Jimenez Freites iD, Mattia Giovannini iD, Mark Kačar iD, Aspasia Karavelia iD, Janice Layhadi iD, Urszula Radzikowska iD, Cezmi A Akdis iD und 15 weitere

Pediatric Allergy and Immunology · 2026

DOI: 10.1111/pai.70407 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Allergy and Immunology, 2026. Verfasst von Riccardo Castagnoli und 26 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Unit, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Precision Medicine, Hypersensitivity, Allergy and Immunology, Rare Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clemens von Pirquet Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric immunological and allergic conditions represent a broad spectrum, ranging from highly prevalent polygenic disorders (e.g., food allergy, atopic dermatitis, asthma, and allergic rhinitis) to rarer monogenic primary atopic disorders. The management of these conditions has undergone a paradigm shift in recent years. Moving away from a “one‐size‐fits‐all” approach, precision medicine aims to deliver the right treatment to the right patient at the right time. By integrating clinical phenotypes with molecular endotypes and using specific biomarkers and “Omics” techniques, scientists and clinicians can now employ targeted biological therapies that significantly improve patient outcomes. By identifying early therapeutic windows and specific biomarkers, pediatric specialists can implement personalized interventions that halt the atopic march and mitigate the global burden of chronic allergic diseases. By shifting the focus from symptom management to the neutralization of specific molecular pathways, it is now possible to achieve better disease control, reduce side effects associated with broad‐spectrum treatments such as systemic corticosteroids, and improve the quality of life for patients with refractory allergic diseases. This review, generated during a seminar funded by the Clemens von Pirquet Foundation, aims to delineate the “rare to common” pipeline, illustrating how precision medicine tools, including multi‐omics, biomarkers, and artificial intelligence methods, can connect mechanistic pathways across the immunological spectrum. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineHypersensitivityAllergy and ImmunologyRare DiseasesHumansChildPediatricsBiomarkers

Stichwörter der Autor:innen

allergybiologicsinborn errors of immunity (IEI)pediatricsprecision medicineprimary atopic disorders (PAD)small molecules

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Pediatric Unit, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.
  • Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Maternity and Pediatric Department, Azienda Sanitaria Locale, Benevento, Italy.
  • Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
  • Immunology Department, IIS-Fundación Jiménez Díaz, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Pediatric Department, Pediatric Allergy Out-Clinics, Consorci Sanitari Alt Penedès-Garraf, Barcelona, Spain.

ORCID-Profile: Riccardo Castagnoli, Martina Votto, Ivan Taietti, Maria Isabel Delgado-Dolset, Rubén Fernández-Santamaría, Martha Jimenez Freites, Mattia Giovannini, Mark Kačar, Aspasia Karavelia, Janice Layhadi, Urszula Radzikowska, Cezmi A Akdis, Mubeccel Akdis, Marketa Bloomfield, Francesco Cinetto, Antoine Deschildre, Jonathan Hourihane, Susanne Lau, Antonio Nieto-Garcia, Ismail Ogulur, Liam O'Mahony, Mohamed Shamji, Milena Sokolowska, Maria Jose Torres, Sophia Tsabouri, Philippe Eigenmann

Förderung

  • Clemens von Pirquet Foundation

Zitieren

APA

Castagnoli, R., Votto, M., Taietti, I., Delgado-Dolset, M. I., Fernández-Santamaría, R., Jimenez Freites, M., Giovannini, M., Kačar, M., Karavelia, A., Layhadi, J., Radzikowska, U., Akdis, C. A., Akdis, M., Bloomfield, M., Cinetto, F., Deschildre, A., Hourihane, J., Lau, S., Nieto-Garcia, A., …, & EAACI‐Clemens von Pirquet Foundation (2026). Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70407

Vancouver

Castagnoli R, Votto M, Taietti I, Delgado-Dolset MI, Fernández-Santamaría R, Jimenez Freites M, et al. Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology. Pediatric Allergy and Immunology. 2026. doi:10.1111/pai.70407

BibTeX
@article{Castagnoli2026,
  author = {Castagnoli, Riccardo and Votto, Martina and Taietti, Ivan and Delgado-Dolset, Maria Isabel and Fernández-Santamaría, Rubén and Jimenez Freites, Martha and Giovannini, Mattia and Kačar, Mark and Karavelia, Aspasia and Layhadi, Janice and Radzikowska, Urszula and Akdis, Cezmi A and Akdis, Mubeccel and Bloomfield, Marketa and Cinetto, Francesco and Deschildre, Antoine and Hourihane, Jonathan and Lau, Susanne and Nieto-Garcia, Antonio and Ogulur, Ismail and O'Mahony, Liam and Shamji, Mohamed and Sokolowska, Milena and Torres, Maria Jose and Tsabouri, Sophia and Eigenmann, Philippe and EAACI‐Clemens von Pirquet Foundation, EAACI‐Clemens von Pirquet Foundation},
  title = {Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology},
  journal = {Pediatric Allergy and Immunology},
  year = {2026},
  doi = {10.1111/pai.70407}
}
Kostenlos starten →